NCT07171606RecruitingPhase 2
A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients
Source: ClinicalTrials.gov · Last updated 18 Dec 2025
Brief summary (registry, in English)
This study includes two parts, part 1 is SSGJ-706 monotherapy therapy for advanced NSCLC and part 2 is SSGJ-706 combination therapy for advanced NSCLC
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 240 (estimated)
- First submitted
- 1 Sept 2025
- Start date
- 24 Oct 2025
- Primary completion date
- 31 Aug 2026
- Lead sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
- Diseases
- Lung cancer
- NCT number
- NCT07171606
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 240
- From 24 Oct 2025 to the primary completion date, 31 Aug 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Adverse events (with exception of alopecia and fatigue) from any prior anticancer therapy of grade \>1 (National Cancer Institute Common terminology Criteria \[NCI CTCAE\] v.5.0).
Other illness
- Known uncontrolled or symptomatic central nervous system metastatic disease.
- Known allergies, hypersensitivity, or intolerance to SSGJ-706
- The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Other
- Inadequate organ or bone marrow function.
- Pregnant or breast-feeding woman.
Who the study is looking for
- Males and/or females over age 18
- Histologically and/or cytologically documented local advanced or metastatic NSCLC .
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
- Expected survival \>=3 months.
- Signed informed consent form.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institute of The Shanghai Pulmonary Hospital Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.